SAN DIEGO, Aug. 14, 2017 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of liquid biopsy
tests designed to provide physicians with clinically actionable
information to improve the outcomes of cancer patients, announces
that it has signed an exclusive global Distribution Agreement
excluding China, for the Company's
proprietary blood collection tubes (BCTs) with VWR International,
LLC (VWR), the leading global independent provider of product and
service solutions to laboratory and production customers. Biocept's
BCTs allow for the intact transport of liquid biopsy samples for
research use only from regions around the world. Commercial launch
is anticipated to begin in the second half of 2017.
The patented BCTs were developed at Biocept, and, over the past
four years, have been used to transport thousands of patient
samples containing both circulating tumor DNA (ctDNA) and
circulating tumor cells (CTCs). Specimen types successfully
transported with this technology include blood, cerebrospinal
fluid, sputum, and fluid obtained from pleural effusion. Use of the
Company's BCTs does not require pre-shipment specimen processing,
refrigeration during shipping, or centrifugation upon receipt,
which can be barriers to the adoption of liquid biopsy. Study data
demonstrating the ability to successfully collect and preserve
patient blood samples for use with single gene tests and a broad
liquid biopsy panel were presented in a poster at the 2017 American
Association for Cancer Research (AACR) Annual Meeting in April.
"Our patented blood collection tubes are designed to facilitate
the high-growth potential of liquid biopsy, and our agreement with
VWR can help us leverage this opportunity in scale," said
Mike Terry, Senior Vice President,
Commercial Operations. "Collection and preservation of patient
samples are key requirements to perform liquid biopsy, and given
our historic use of these tubes for the transport and preservation
of many liquid biopsy specimens, we believe that our BCTs offer a
clinically robust solution."
Michael Nall, Biocept's President
and CEO, added, "We are very proud to be working with VWR, for the
distribution of our proprietary liquid biopsy collection tubes.
Entering into the global market with a scaled offering for liquid
biopsy is the first step toward growing from an exclusive CLIA lab
business to a technology and products company. The development of
this important technology is a prime example of how Biocept intends
to leverage its proprietary technologies and intellectual property
to improve the standard of care for cancer patients and to increase
the value of our Company for shareholders."
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its proprietary
liquid biopsy technology to provide physicians with clinically
actionable information for treating and monitoring patients
diagnosed with cancer. The Company's patented Target Selectorâ„¢
liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. For additional
information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This news release contains forward-looking statements that are
based upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
be correct. Forward-looking statements are generally identifiable
by the use of words like "may," "will," "should," "could,"
"expect," "anticipate," "estimate," "believe," "intend" or
"project," or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this news release are not strictly historical,
including, without limitation, statements as to our ability to
improve the outcomes of cancer patients, increase revenue or sales,
the utility and effectiveness of our intellectual property
protections, and our ability to drive additional value of the
Company, such statements are forward-looking, and are made pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our Securities
and Exchange Commission (SEC) filings. The effects of such risks
and uncertainties could cause actual results to differ materially
from the forward-looking statements contained in this news release.
We do not plan to update any such forward-looking statements and
expressly disclaim any duty to update the information contained in
this press release except as required by law. Readers are advised
to review our filings with the SEC at www.sec.gov.
View original content with
multimedia:http://www.prnewswire.com/news-releases/biocept-enters-into-exclusive-distribution-agreement-with-global-laboratory-product-supplier-vwr-300503561.html
SOURCE Biocept, Inc.